PTO/SB/30 (07-09)

Under the Paperwork Reduction Act of 1995, no persons are require	U.S. Patent and Trade	vroved for use through 07/31/2012. OMB 0651-0031 emark Office; U.S. DEPARTMENT OF COMMERCE ation unless it contains a valid OMB control number.
Request	Application Number	10/561,543
for	Filing Date	December 19, 2005
Continued Examination (RCE) Transmittal	First Named Inventor	Katsuhiko KYUKEN
Address to:	Art Unit	3653
Mail Stop RCE Commissioner for Patents	Examiner Name	T. A. Morrison
P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket Number	0951-0177PUS1
This is a Request for Continued Examination (RCE) u	inder 37 CFR 1.114 of the ab	ove-identified application.
Request for Continued Examination (RCE) practice under 37 CF 1995, or to any design application. See Instruction Sheet for RC	R 1.114 does not apply to any uti Es (not to be submitted to the USI	lity or plant application filed prior to June 8, PTO) on page 2.
Submission required under 37 CFR 1.114 Not amendments enclosed with RCE will be entered in the applicant does not wish to have any previously filed unent enrendment(s). Previously submitted. If a final Office action is c	e order in which they were filed un tered amendment(s) entered, appl	less applicant instructs otherwise. If licant must request non-entry of such
considered as a submission even if this box is not checked.		
i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on		
li. Other Amendment After Final filed on Ju	ıly 13, 2010	
b Enclosed		
I. Amendment/Reply	The same	Disclosure Statement (IDS)
ii. Affidavit(s)/ Declaration(s)	iv. Other	
Miscellaneous Suspension of action on the above-identified a period of	pplication is requested under 37 to on shall not exceed 3 months; Fee und	CFR 1.103(c) for a ler 37 CFR 1.17(i) required)
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 02-2448		
i. RCE fee required under 37 CFR 1.17(e)		
ii. Extension of time fee (37 CFR 1.138 and 1.17)		
iii. Other		
b. Check in the amount of \$	enclosed	
c. Payment by credit card (Form PTO-2038 encloses	,	
WARNING: Information on this form may become public. Cre card information and authorization on PTO-2038.	edit card information should not	be included on this form. Provide credit
SIGNATURE OF APPLICA	IT, ATTORNEY, OR AGENT RE	
Signature R. A. Doron # 4/82 Name (Print/Type) Michael R. Cammarata	2Z Date	August 13, 2010 stration No. 30401
		stration No. 39491
	MAILING OR TRANSMISSION	
hereby certify that this correspondence is being deposited with the United addressed to. Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, office on the date shown below.	States Postal Service with sufficient p Alexandria, VA 22313-1450 or facsimi	oostage as first class mail in an envelope le transmitted to the U.S. Patent and Trademark
Signature Name (Print/Type)		
This collection of information is required by 37 CFR 1.114. The information	Date n is required to obtain or retain a bene	fit by the public which is to file (and by the USPTO

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public winds is to line, (armay in use vol. process) an application. Confiderability is governed by 38 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete properties, and submitting the completed application form to the USP10. Time will vary depending upon the information of the individual cases. Any commercial control in the amount of time you require to complete this form another upon supporting be burden, should be sent to the Chief Information Officer, U.S. Patient and Traditionals Office. U.S. Patient and Traditionals Office. U.S. Patient and State of the Chief Information Officer, U.S. Patient and Traditionals Office. U.S. Patient and State of the Chief Information Officer, U.S. Patient and Traditionals Office. U.S. Patient and State of the Chief Information Officer, U.S. Patient and Traditionals Officer. U.S. Patient and State of the Chief Information Officer. U.S. Patient and Traditionals Officer. U.S. Patient and State of the Chief Information Officer. U.S. Patient and Traditionals Officer. U.S. Patient and Traditionals Officer. U.S. Patient and State of the Chief Information Officer. U.S. Patient and Traditionals Officer. U.S. Patient and Traditionals Officer. U.S. Patient and Traditionals Officer. U.S. Patient and Traditional Officer. U.